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Previous work indicates that RhoA phosphorylation
on Ser188 by cAMP or cGMP-dependent kinases inhibits
its activity. However, these studies lacked the possibil-
ity to directly study phosphorylated RhoA activity in
vivo. Therefore, we created RhoA proteins containing
phosphomimetic residues in place of the cAMP/cGMP-
dependent kinase phosphorylation site. RhoA phospho-
rylation or phosphomimetic substitution did not affect
Rho guanine nucleotide exchange factor, GTPase acti-
vating protein, or geranylgeranyl transferase activity in
vitro but promoted binding to the Rho guanine-dissoci-
ation inhibitor as measured by exchange factor compe-
tition assays. The in vitro similarities between RhoA
phosphomimetic proteins and phosphorylated RhoA al-
lowed us to study function of phosphorylated RhoA in
vivo. RhoA phosphomimetic proteins display depressed
GTP loading when transiently expressed in NIH 3T3
cells. Stable-expressing RhoA and RhoA(S188A) clones
spread significantly slower than mock-transfected or
RhoA(S188E) clones. RhoA(S188A) clones were pro-
tected from the morphological effects of a cAMP agonist,
whereas phosphomimetic clones exhibit stress fiber dis-
assembly similar to control cells. Together, these data
provide in vivo evidence that addition of a charged
group to Ser188 upon phosphorylation negatively regu-
lates RhoA activity and indicates that this occurs
through enhanced Rho guanine-dissociation inhibitor
interaction rather than direct perturbation of guanine
nucleotide exchange factor, GTPase activating protein,
or geranylgeranyl transferase activity.
The intracellular protein RhoA, a member of the Ras super-
family of low molecular weight G proteins, regulates cell cycle
progression, gene expression, focal adhesion assembly/disas-
sembly, and the acto-myosin generated contraction and tension
events of cell motility, matrix remodeling, and cytokinesis (1).
RhoA cycles between an active GTP-bound and an inactive
GDP-bound state through nucleotide exchange and intrinsic
GTPase activity. During cellular events of RhoA activation,
guanine nucleotide exchange factors (GEFs)1 can bind and
activate RhoA by promoting uptake of free nucleotide (2).
GTPase activating proteins (GAPs) negatively regulate RhoA
by binding and stimulating GTP hydrolysis leading to an inac-
tive GDP-bound state (3). RhoA signals within the cell by
binding to a variety of effector molecules, such as mDia and the
Rho kinases ROK/ROCK2 and ROK/ROCK1 (4–6). The vast
majority of RhoA (95%) resides in the cytosolic fraction of the
cell (7, 8), with the remainder associated with lipid membranes
via a geranylgeranyl moiety attached to a carboxyl Cys190
residue (9). Prenylation of RhoA is required for promotion of
cell growth, transformation, and cytoskeletal organization, in-
dicating that membrane cycling is a critical component of Rho
regulation (10). A primary mechanism of cytosolic sequestra-
tion of RhoA is through binding of Rho guanine-dissociation
inhibitors (RhoGDIs) (11). RhoGDI contacts RhoA through two
distinct domains, a flexible amino-terminal domain that im-
pedes guanine nucleotide dissociation/hydrolysis and a highly
folded carboxyl domain that stabilizes the RhoA geranylgera-
nyl moiety (12). RhoGDI is postulated to extract RhoA from
membranes through concerted actions of both domains (11).
Administration of forskolin, an activator of adenylate cy-
clase, or dibutyryl cAMP to cells stimulates morphological
changes that are strikingly similar to those observed upon
introduction of the Rho-specific inhibitor C3-transferase (13).
From this initial observation, cAMP- and cGMP-dependent
kinase (PKA and PKG) were demonstrated to phosphorylate
RhoA on Ser188 (13, 14), thereby joining RhoA with Rap1a and
Rap1b as small GTPases regulated by carboxyl PKA phospho-
rylation (15, 16). Although PKA phosphorylation is linked to
Rap activation (17, 18), evidence indicates that it negatively
regulates RhoA function. RhoA phosphorylation promotes for-
mation of RhoARhoGDI complexes (13, 19) and enhances the
ability of RhoGDI to extract RhoA from membranes (13, 20). In
support of enhanced RhoGDI binding, the ability of RhoA to
cycle from membranes has been linked to cAMP and cGMP
signaling within cells (21, 22). Functionally, constitutively ac-
tive RhoA containing an S188A mutation is more effective in
blocking actin dissolution promoted by dibutyryl cAMP (23) or
8-Bromo-cGMP (24), and constitutively active RhoA require a
S188A mutation to promote stress fibers in cells co-transfected
with constitutively active PKG (14).
On the other hand, the significance of RhoA phosphorylation
to PKA/PKG regulation of its signaling is unclear considering
recent reports. Thromboxane receptor stimulation promotes
RhoA activation through a G13 and a PKA-sensitive path-
way(s) (25). Manganello et al. (26) demonstrated recently that
PKA phosphorylates G13 subunit to promote  subunit un-
coupling, thereby effectively shutting down receptor activation
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of RhoA. Moreover, PKG inhibited G13 activation of serum
response factor transcription by impeding activation of RhoA
(27). Notably, PKG also inhibited serum response factor tran-
scriptional activity promoted by constitutively active forms of
Rho kinase, protein kinase N, or protein kinase C-related ki-
nase 2, indicating that PKG antagonizes RhoA signaling down-
stream of effector regulation. Thus, an emerging picture is that
PKA/PKG negatively regulates RhoA at multiple levels.
In this work, we expressed Ser188 phosphomimetic RhoA
proteins, in the absence of constitutive RhoA activity and ab-
errant PKA/PKG signaling, to assess the contribution of PKA
phosphorylation to RhoA function. We report here that addi-
tion of a charged group to Ser188 upon phosphorylation nega-
tively regulates RhoA activity in vivo and indicates that this
occurs through enhanced RhoGDI interaction rather than di-
rect perturbation of GEF, GAP, or geranylgeranyl transferase
activity.
EXPERIMENTAL PROCEDURES
Materials—Puromyocin, bovine serum albumin, and buffer reagents
were acquired from Sigma. Polyvinylidene fluoride membranes were
purchased from Millipore. RhoA monoclonal antibodies (clone 55) were
purchased from BD Biosciences. NIH 3T3 cells were maintained in
growth medium (Dulbecco’s modified Eagle’s medium supplemented
with 10% bovine calf serum (Sigma)).
Constructs—RhoA mutations (S188A, S188D, S188E, C190A) and
RhoG mutation (S187A) were created through PCR mutagenesis using
the QuikChange mutagenesis kit (Stratagene). Mutations were con-
firmed by DNA sequencing, and cDNAs were subcloned into either
pGEX4T-1 (Amersham Biosciences) or pCMV-Myc (Clontech) using
EcoRI and XhoI restriction sites. pGEX4T-1-RhoGDI (human) was cre-
ated by subcloning RhoGDI cDNA into pGEX4T-1 using BamHI and
EcoRI restriction sites. pPro-HT-Dbl (DH/PH) was a gift of Dr. K.
Rossman, University of North Carolina, Chapel Hill, NC.
Antibody Production—Antibody production and purification was per-
formed by Covance Research Products Inc. Rabbits were immunized
with a phosphoserine peptide containing the proximal nine residues of
RhoA (RRGKKKPSGC) thiol bonded to keyhole limpet hemocyanin.
Antibodies were isolated by negative affinity purification with immobi-
lized unphosphorylated RhoA peptide followed by positive affinity pu-
rification with immobilized phosphorylated RhoA peptide and low/high
pH elutions.
Fusion Proteins—GST-Rho fusion proteins (GST, GST-RhoA, GST-
RhoG, GST-Cdc42, GST-Rac1, GST-RhoGDI) were purified from BL21
Escherichia coli cells (Stratagene) using glutathione-Sepharose 4B
(Amersham Biosciences). Proteins were eluted with free and reduced
glutathione in Tris-buffered saline medium (50 mM Tris, 150 mM NaCl,
5 mM MgCl2, 1 mM dithiothreitol) and stored in 30% glycerol. His6-Dbl
DH/PH was purified from BL21 E. coli cells using nickel-nitrilotriacetic
acid-Sepharose (Qiagen) and eluted with 20 units of tobacco etch virus
protease (Invitrogen) according to the manufacturer’s specifications.
RhoGDI was produced by cleaving RhoGDI from GST-RhoGDI-Sepha-
rose with 5 units of bovine thrombin (Sigma). RhoGDI was subse-
quently cleared with benzamidine-agarose (Sigma) to remove thrombin
from incubation buffer. Recombinant geranylgeranyl transferase was
purchased from Sigma. Phosphate-binding protein carrying an A197C
mutation was purified and fluorescently labeled with N-[2–1-maleimi-
dyl)ethyl]-7-(diethylamino)coumarin-3-carboxamide as described previ-
ously (28) from E. coli ANCC75 bacteria carrying plasmid pSN5182/7 (a
kind gift of Dr. M. R. Webb, National Institute for Medical Research,
London). His6-Larg DH/PH and His6-Vav2 DH/PH/CRD were kind gifts
of Dr. M. Booden, University of North Carolina, Chapel Hill, NC.
His6-DH/PH Dbs was a gift of Dr. K. Rossman, University of North
Carolina, Chapel Hill, NC. Full-length p190RhoGAP was a generous
gift of Dr. J. Settleman, Harvard Medical School.
Rho Protein Phosphorylation—To measure cPKA phosphorylation of
Rho fusion proteins (see Fig. 1), 2.0 pmols of fusion proteins, 1.5 units
of cPKA (Sigma), 330 pmols of ATP, and 3.3 pmols of [-32P]ATP
(Amersham Biosciences) were incubated in phosphorylation buffer (50
mM Tris, 5 mM MgCl2, 1 mM dithiothreitol) at 30 °C for 20 min. Samples
were removed, resolved by 15% SDS-PAGE, and then analyzed by
autoradiography of dried gels. For large scale production of phospho-
rylated GST-RhoA, 120 g (2.5 nmols) of GST-RhoA-Sepharose, 150
units of cPKA, and excess ATP (2 mM) were rotated in 1 ml of phospho-
rylation buffer for 90 min at 25 °C. Phosphorylation efficiency was
estimated by scaling down reaction to 1% the amount of GST-RhoA and
cPKA. Specifically, 1.2 g (25 pmols) of GST-RhoA-Sepharose, 1.5 units
of cPKA, 2.12 nmols of ATP, and 3.3 pmols of [-32P]ATP (1:645 dilu-
tion) were incubated in 10 l of phosphorylation buffer with rotation for
30 min at 25 °C. Reactions were washed extensively, and incorporation
of 32P was calculated and corrected with values obtained from GST-
Sepharose reactions. On average, 0.030–0.035 pmols of 32P was incor-
porated by RhoA into each reaction, indicating 80–90% phosphorylation
efficiency ((645  0.03 pmol)/25 pmol GST-RhoA). To measure phospho-
rylation of geranylgeranylated RhoA, 2.0 pmol of unmodified or pre-
nylated RhoA (see below) were incubated with 1.5 units of cPKA, 330
pmols of ATP, and 3.3 pmols of [-32P]ATP in phosphorylation buffer at
30 °C for 20 min. Samples were boiled to stop the reaction and then
TX-114 was added to a concentration of 1%, and phase partitioning was
performed as described previously for Rho proteins (29). The detergent
phase was washed with three 20-fold volumes of phosphate-buffered
saline to ensure removal of non-prenylated RhoA. Both aqueous and
detergent phases were aliquoted and analyzed for RhoA phosphoryla-
tion by measuring release of radioactivity and visualizing by SDS-
PAGE and autoradiography.
In Vitro Guanine Nucleotide Exchange Factor Assays—Fluorescence
spectroscopic analysis of N-methylanthraniloyl (mant)-GTP (Biomol)
incorporation into GDP-preloaded GST-Rho proteins was carried out
using a FLUOstar fluorescence microplate reader at 25 °C similar to as
described previously (30). 2 M GST-RhoA or 1 M prenylated GST-
RhoA was prepared and allowed to equilibrate in exchange buffer (20
mM Tris, pH 7.5, 50 mM NaCl, 10 mM MgCl2, 1 mM dithiothreitol, 50
g/ml bovine serum albumin, 1% glycerol). 500 nM mant-GTP and
varying amounts of DH/PH (Larg, Dbl, or Dbs) or DH/PH/CRD (Vav2)
protein were added at the indicated time, and the relative mant fluo-
rescence (excitation  360 nm, emission  460 nm) was monitored.
Experiments were performed in duplicate for every condition.
GAP Assays—GAP assays were performed in a Spectramax Gemini
XS fluorescence microplate reader (Molecular Devices) (excitation 
425 nm, emission  465 nm) at 25 °C by incubating 1 M GTP-loaded
GST-RhoA together with 2.5 M fluorophore-labeled phosphate-binding
protein in the absence or presence of 250 or 750 pM purified
p190RhoGAP in a buffer containing 20 mM Tris, pH 7.6, and 1 mM
MgCl2 at a total volume of 100 l. Upon hydrolysis of GTP, the resulting
free Pi is bound rapidly (1.36  10
8 M1 s1 at 22 °C) and with high
affinity (about 100 nM) by the phosphate-binding protein, resulting in a
13-fold increase in the fluorescence at 465 nm (28). Because of this, the
observed change in fluorescence corresponds to the rate and amount of
Pi released from the GTPase.
RhoGDI Competition Assays—2 M of the indicated GST-RhoA fu-
sion protein was incubated for 10 min in exchange buffer containing 0.5,
1.0, or 2.0 M RhoGDI to promote RhoARhoGDI complexes. Vav2
DH/PH/CRD and mant-GTP nucleotides were then added and allowed
to equilibrate with mixing for 15 s, and the rate of mant-GTP incorpo-
ration was measured. Linear velocity of exchange was determined as
described previously (31). Briefly, baseline and GEF-induced nucleotide
exchange rates were calculated by dividing the change in emission at
460 nm by change in time. Values were averaged and standard devia-
tions were calculated for each reaction. Velocity was considered linear
as long as the regression value of the exchange slope was greater than
0.97. Data from these and all other experiments were considered sig-
nificantly different if the p values, as determined by two-tailed t tests,
were 0.02.
Geranylgeranyl Transferase Assays—GST or the indicated GST-
RhoA-Sepharose (5 pmols), 100 pmols of 3H-geranylgeranyl pyrophos-
phate (PerkinElmer Life Sciences), and 0.36 units of geranylgeranyl
transferase were incubated in Tris-buffered saline medium, pH 7.6, for
20 or 60 min. Samples were resolved by 15% SDS-PAGE, and gels were
fixed, incubated in Amplify solution (Amersham Biosciences), and then
exposed by autoradiography. Alternatively, reactions were collected at
20, 40, 60, and 80 min in duplicate, washed extensively, and placed in
scintillation buffer, and the extent of 3H-geranygeranyl was quantified.
To generate geranylgeranylated RhoA for kinetic assays, 50 g (1 nmol)
of GST-RhoA or phosphorylated GST-RhoA were incubated in solution
with geranylgeranyl pyrophosphate (25 nmols) and in the absence or
presence of 10 units of geranylgeranyl transferase overnight at 30 °C.
Proteins were either GDP-loaded (GEF assays) or GTP-loaded (GAP
assays) and eluted with small volumes of free glutathione in Tris-
buffered saline containing 0.25% deoxycholate. Through dilutions, re-
actions contained either 0.025% (GEF) or 0.015% deoxycholate (GAP).
Unmodified RhoA (no transferase) was utilized as an experimental
control for the influence of prenylation on GTPase activity (see Fig. 5, C
and D).
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Transfections and Production of Stable Cells—NIH 3T3 fibroblast
cells were transfected with the expression vectors indicated in each
experiment according to the manufacturer’s protocol using Lipo-
fectAMINE PLUS (Invitrogen). After introduction of the expression
vectors for 3 h, the transfection medium was replaced with growth
medium for 16 h. For creation of stable cell lines, NIH 3T3 cells were
transfected with 1 g of pPUR (Clontech) only or cotransfected with
0.05 g of pPUR and 1 g of pCMV-Myc RhoA construct and then
selected in 10 g/ml puromycin (Sigma). Clonal lines were established
and screened for expression by Western blotting lysates with anti-c-Myc
(clone 9E10; Sigma) monoclonal antibodies.
RhoA GTP Profile Assays—The amount of activated, GTP-bound
RhoA protein was measured using a technique similar to the method
described by Ren et al. (32). Briefly, transfected or stable cells were
lysed in 300 l of 50 mM Tris, pH 7.4, 10 mM MgCl2, 500 mM NaCl, 1%
Triton X-100, 0.1% SDS, 0.5% deoxycholate, and protease inhibitors.
500–750 g of lysates were cleared at 16,000  g for 5 min, and the
supernatant was rotated for 30 min with 30 g of GST-RBD (GST fusion
protein containing the Rho-binding domain (RBD; amino acids 7–89) of
Rhotekin) bound to glutathione-Sepharose beads. Samples were
washed in 50 mM Tris, pH 7.4, 10 mM MgCl2, 150 mM NaCl, 1% Triton
X-100, and protease inhibitors. GST-RBD pulldowns and lysates were
then Western blotted with anti-c-Myc. To quantify GST-RBD pull-
downs, Western blots of lysates and corresponding GST-RBD pulldowns
from three unique experiments done in duplicate were scanned, and
densitometry was performed using Metamorph imaging software.
Calculation of Cell Spreading—For all experiments cells were re-
plated in the absence of puromycin the day before experiments,
trypsinized, washed twice in Dulbecco’s modified Eagle’s medium, and
then suspended before plating for 30 min in Dulbecco’s modified Eagle’s
medium and 0.5% fatty acid-free bovine serum albumin. Suspended
cells were plated on fibronectin-coated coverslips for 20, 40, and 60 min.
Coverslips were fixed and stained with Coomassie Blue (2% Brilliant
Blue, 45% methanol, and 10% acetic acid) for 10 min and then washed
with water and mounted. The relative areas of individual cells from
Metamorph images were quantified with the use of NIH Image soft-
ware. At least 50 cells taken from 10 arbitrary fields were counted from
each coverslip, with two coverslips counted for every condition.
Immunofluorescence—Cells were plated and grown overnight on fi-
bronectin-coated glass coverslips in the presence of serum. Cells were
washed free of serum with serum-free medium and then incubated in
serum-free media containing either Me2SO vehicle or 25 M forskolin
(Sigma) for 20 min. Cells were then fixed for 15 min in 3.7% formalde-
hyde in phosphate-buffered saline permeabilized for 5 min in 0.5%
Triton X-100 in phosphate-buffered saline. Filamentous actin was la-
beled with Texas Red-conjugated phalloidin (Molecular Probes). Images
were obtained on an Axiophot microscope (Zeiss) using a MicroMAX
5-MHz cooled CCD camera (Princeton Instrument) and Metamorph
Image software (Universal Imaging Corp.).
RESULTS
PKA Phosphorylation of Rho Proteins—We confirmed that
PKA phosphorylates RhoA on Ser188 (Fig. 1A) as described
previously (13). Although Forget et al. (19) demonstrated that
PKA also phosphorylates Cdc42, we found Cdc42 to be a poor
substrate for PKA in vitro, in agreement with an initial report
(33). Further, Rac1 was not phosphorylated, whereas PKA
efficiently phosphorylates RhoG on Ser187 (Fig. 1A), indicating
that both RhoA and RhoG carboxyl termini are targets of PKA
phosphorylation. The proximity of the Rho prenylation site
(residue 190) to the site of PKA phosphorylation prompted us to
examine whether prenylation affects PKA phosphorylation. Al-
though RhoA is efficiently prenylated in our reactions (60–80%
by molar incorporation of 3H-geranylgeranyl pyrophosphate),
phosphorylated RhoA or geranylgeranylated RhoA (ggRhoA)
were subjected to TX-114 phase extraction. TX-114 phase ex-
traction partitions prenylated RhoA into the detergent phase
because of the hydrophobic modification (29), ensuring that
ggRhoA will be specifically examined as a substrate. Phospho-
rylation efficiency of RhoA and ggRhoA was comparable (Fig. 1,
B and C), demonstrating that prenyl modification of RhoA does
not impede PKA phosphorylation. To measure cellular RhoA
phosphorylation, we generated affinity-purified antibodies that
selectively recognize phospho-Ser188 RhoA (Fig. 2A). Charac-
terization of two unique antisera revealed that geranylgerany-
lation of phosphorylated GST-RhoA proteins abrogated anti-
body binding (Fig. 2A), indicating that the presence of a C20
isoprenoid moiety sterically blocks antibody recognition. There-
fore, we elected to use NIH 3T3 cells that stably express Myc
epitope-tagged-RhoA(C190A) to measure cellular PKA phos-
phorylation of Ser188. Forskolin stimulation of cAMP produc-
tion strongly enhanced Myc-RhoA(C190A) phosphorylation as
measured by Western blotting of whole cell lysates or immu-
noprecipitated proteins (Fig. 2B). We and others (32, 34) have
established previously that RhoA activity is reduced during the
initial 15–30 min of cell spreading. Interestingly, PKA activity
is transiently stimulated during the same time course (35). To
address whether RhoA is a PKA target during spreading, cells
expressing Myc-RhoA(C190A) were allowed to spread on fi-
bronectin and at various times collected for immunoprecipita-
tion with phospho-Ser188 antibodies. We observed that cellular
phosphorylation of RhoA was significantly increased within the
initial 20 min of NIH 3T3 cell spreading on fibronectin (Fig.
2C). These data support the conclusion that cellular PKA ac-
tivity is elevated early in spreading (35, 36) and indicates that
RhoA is a target of cellular PKA regulation.
GEF Exchange against Phosphorylated RhoA—GEFs bind
GDP-bound Rho proteins and induce a transition state that
promotes uptake of free GTP nucleotide, thereby stimulating
Rho activation. It has been reported that cAMP inhibits GEF
activation of RhoA in leukocytes (37), thereby raising the pos-
sibility that RhoA phosphorylation impairs GEF exchange. To
address this hypothesis, GST-RhoA was phosphorylated in
vitro with cPKA and compared with control protein for the
ability of DH/PH domain-containing GEFs to promote nucleo-
FIG. 1. Characterization of Rho protein phosphorylation. A,
GST-Rho fusion proteins were incubated in duplicate, as indicated, with
[-32P]ATP and cPKA, and phosphorylation was visualized by SDS-
PAGE followed by autoradiography. Mutation of Ser188 and Ser187
blocks cPKA phosphorylation of RhoA and RhoG, respectively. B, GST-
RhoA was incubated with geranylgeranyl pyrophosphate in the absence
or presence of geranylgeranyl transferase to produce control and pre-
nylated RhoA (ggRhoA). RhoA and ggRhoA fusion proteins were phos-
phorylated with [-32P]ATP and cPKA and then subjected to TX-114
detergent partitioning as described previously (29). Phosphorylation
(cpm) of unmodified RhoA, which remains associated with the aqueous
phase, and of prenylated RhoA, which partitions into the TX-114 deter-
gent phase, was measured for each reaction. Values are expressed as
percent of total amount found in both phases (19,670 cpm for RhoA and
13,796 cpm for ggRhoA  S.D.) and were corrected for the low contri-
bution of kinase-bound radioactivity. C, RhoA and ggRhoA phosphoryl-
ation were visualized by analyzing 10% of the phase volume or 25% of
the TX-114 phase volume by SDS-PAGE followed by autoradiography.
TX-114 phase proteins run as wider bands because of the Triton deter-
gent. Phosphorylation of prenylated RhoA was readily evident in the
assay, demonstrating that prenylation does not interfere with the cat-
alytic activity of cPKA against Ser188.
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tide uptake. Using [-32P]ATP, GST-RhoA was estimated to be
at least 80–90% phosphorylated by cPKA. Basal incorporation
of mant-GTP was identical for phosphorylated and control
GST-RhoA proteins (Fig. 3A). Larg (Fig. 3A), Vav-2 (Table I),
Dbl, and Dbs (not shown) all displayed similar exchange activ-
ity against control and phosphorylated GST-RhoA at multiple
GEF concentrations. This finding also extended to phosphoryl-
ated and control geranylgeranylated RhoA proteins (Fig. 3B).
Lastly, the phosphomimetics GST-RhoA(S188E) and GST-
RhoA(S188D) were equivalent substrates as wild-type GST-
RhoA or GST-RhoA(S188A) controls (Fig. 3C). These data dem-
onstrate that phosphorylation of the RhoA tail does not directly
interfere with GEF-induced exchange.
RhoA Ser188 Phosphomimetics Display Increased Binding to
RhoGDI—cPKA-phosphorylation of RhoA has been reported to
increase its affinity toward RhoGDI, therefore we examined the
ability of RhoGDI to bind RhoA proteins using solution-phase
binding competition of RhoGDI and GEF molecules. Briefly,
GST-RhoA proteins were pre-incubated with no or varying
amounts of full-length RhoGDI for 10 min to promote the
formation of RhoARhoGDI complexes. Vav2 DH/PH/CRD and
mant-GTP nucleotides were subsequently added and allowed to
equilibrate with mixing for 15 s and then mant-GTP incorpo-
ration was measured. Vav2 exchange was linear over the initial
150–200 s for phosphorylated, phosphoserine-mimetics, and
control GST-RhoA proteins (see Fig. 4A and Tables I and II). As
RhoGDI concentrations were increased, the velocity of nucleo-
tide incorporation was both reduced and lengthened for all
RhoA molecules (Tables I and II). Importantly, both phospho-
rylated and phosphomimetic GST-RhoA proteins exhibited a
significant reduction in GEF exchange compared with control
proteins at equal concentrations of RhoGDI (Fig. 4B). The
bulkier S188E mutation resulted in slightly greater inhibition
than the S188D mutation, suggesting tighter binding to
RhoGDI. As prior experiments demonstrated that GEF ex-
FIG. 2. Intracellular RhoA phosphorylation. A, GST-RhoA fusion
proteins were phosphorylated by cPKA as indicated and then incubated
in the absence or presence of geranylgeranyl (gg) transferase. Fusion
proteins were either stained by Coomassie or Western blotted (WB)
with phospho-Ser188 RhoA antibodies isolated from two unique sera
(pserRhoA1 and pserRhoA2). Antibody recognition was sensitive to the
presence of the geranylgeranyl moiety. B, NIH 3T3 cells stably express-
ing Myc-RhoA(C190A) (non-prenylated) were stimulated with 25 M
forskolin (FSK) for 20 min, and lysates were collected and then Western
blotted for recombinant protein (anti-Myc) or RhoA phosphorylation
(pserRhoA1). Only recombinant Myc-RhoA(C190A) was recognized by
pserRhoA1. Additionally, cells were treated as above, and Myc-
RhoA(C190A) immunoprecipitated (IP) with anti-Myc, anti-pserRhoA1,
or irrelevant IgG controls as indicated. Western blots of immunopre-
cipitated material confirm that Myc-RhoA(C190A) is a target of cellular
PKA. Background in the IgG control for the Myc immunoprecipitation
is from the light chain of mouse IgG, which runs at a similar apparent
molecular weight. C, to address whether Myc-RhoA(C190A) is a target
of PKA during an event of low RhoA activity, cells were allowed to
spread on fibronectin for the indicated times, and lysates were collected
and immunoprecipitated with either IgG control or pserRhoA1 antibod-
ies and then Western blotted for the Myc tag. PKA activity and Myc-
RhoA(C190A) phosphorylation were increased within 20 min of cell
spreading.
FIG. 3. RhoA phosphorylation does not affect GEF exchange.
A, phosphorylated or control GST-RhoA were incubated in the presence
of mant-GTP before stimulation of exchange by the addition of the Larg
DH/PH domain at the indicated time (denoted GEF with arrow). Kinet-
ics generated from phosphorylated (white symbol) or control proteins
(black symbol) were indistinguishable. B, phosphorylated (gray curve)
or control (black curve) prenylated RhoA was incubated with Vav2
DH/PH/CRD at the indicated time. Vav2 or Larg (not shown) exchange
against prenylated RhoA fusion proteins is not affected by PKA phos-
phorylation of Ser188. C, GST-RhoA (black symbol), GST-RhoA(S188A)
(gray symbol), and GST-RhoA(S188E) (white symbol) were treated as
above. Larg DH/PH displayed similar activity against GST-RhoA and
the GST-RhoA serine mutants.
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change was equivalent for all RhoA proteins at multiple con-
centrations, these data provide additional evidence to previous
reports that RhoA phosphorylation promotes or stabilizes
RhoARhoGDI complex formation. Moreover, as these proteins
are not post-translationally modified, these data indicate that
adding a negative charge to the carboxyl terminus of RhoA
enhances the protein-protein interactions of RhoA and
RhoGDI.
RhoA Phosphorylation Does Not Affect GAP Activity—RhoG-
APs negatively regulate Rho activity by promoting the intrinsic
GTP-hydrolyzing activity of Rho proteins. As cPKA phospho-
rylation is also hypothesized to negatively regulate RhoA, we
analyzed whether p190RhoGAP activity against phosphoryl-
ated RhoA is perturbed in vitro. Basal and p190RhoGAP-in-
duced GTP hydrolysis by phosphorylated, phosphoserine-mi-
metic, and control GST-RhoA proteins was essentially identical
(Fig. 5, A and B). Moreover, p190RhoGAP activity against
geranylgeranylated RhoA was also insensitive to PKA phos-
phorylation, although prenylated RhoA had a slightly lower
basal and GAP-induced hydrolysis rate (Fig. 5, C and D). To-
gether, these data indicate that phosphorylation of RhoA does
not influence the ability of p190RhoGAP to bind and stimulate
GTPase activity.
RhoA Phosphorylation Does Not Affect Geranylgeranyl
Transferase Activity—Incubation of purified cellular mem-
branes with cPKA promotes RhoA extraction from membranes
by RhoGDI (13, 20). As non-prenylated RhoA is a cellular PKA
target, we analyzed whether cPKA phosphorylation of RhoA
impairs addition of a geranylgeranyl moiety as an additional
level of regulation. Geranylgeranyl transferase possessed
equivalent activity against phosphorylated and control protein
GST-RhoA proteins (Fig. 6, A and B). Further, Ser188 mutants
were also comparable substrates (Fig. 6C). Together, these
data indicate that phosphorylation of the RhoA tail does not
directly alter geranylgeranyl transferase modification of RhoA.
Transient Expression of Ser188 RhoA Mutants—NIH 3T3
cells transiently transfected with Myc epitope-tagged RhoA,
RhoA(S188A), RhoA(S188D), or RhoA(S188E) displayed en-
hanced stress fibers compared with mock-transfected cells
(data not shown), indicating that all transient proteins were
functional. The extent of Myc-RhoA GTP loading was evaluated
using GST-RBD pulldowns (32). Both phosphoserine-mimetic
Myc-RhoA proteins, with Myc-RhoA(S188E) being the more
significant, displayed reduced GTP loading in comparison with
Myc-RhoA and Myc-RhoA(S188A) proteins (Fig. 7). Myc-
RhoA(C190A) proteins were not appreciably GTP-loaded under
these conditions and are included as a negative control for GTP
loading. These data provide evidence that addition of a nega-
tive charge by phosphorylation of Ser188 is sufficient to nega-
tively regulate RhoA activation.
Stable Expression of Ser188 RhoA Mutants—To examine
whether a functional differences exists between Ser188 mutant
RhoA proteins, stable clones of NIH 3T3 cells expressing Myc-
RhoA, Myc-RhoA(S188A), or Myc-RhoA(S188E) were isolated.
Two independent clones were chosen for each based solely on
expression level and characterized further. Western blots re-
vealed that Myc-RhoA migrates at higher apparent molecular
weight than the endogenous RhoA proteins; therefore it was
evident that all clones express Myc-RhoA protein at a signifi-
cantly lower level than endogenous RhoA (Fig. 8A). GST-RBD
pulldowns established that, contrary to transiently expressed
proteins; there is little or no difference in the GTP-loading
profile of stably expressed mutant Myc-RhoA proteins, with the
exception of the non-prenylated mutant, Myc-RhoA(C190A)
(Fig. 8B).
Activity of Stably Expressed RhoA Protein—As RhoA is hy-
pothesized to antagonize cell spreading (34), NIH 3T3 clones
were allowed to spread on fibronectin and collected at the
indicated time, and rates of cell spreading were quantified (Fig.
9A). Both Myc-RhoA(S188E) clones spread at a similar rate as
a pool of mock-transfected clones, whereas all the Myc-RhoA
and Myc-RhoA(S188A) clones spread significantly slower. Ad-
ditionally, a pool of Myc-RhoA(S188E)-expressing cells (five
clones) that express a higher amount of Myc-RhoA (Fig. 9B,
inset) still spread significantly faster than a corresponding pool
of Myc-RhoA(S188A)-expressing cells (Fig. 9B).
RhoA signaling has been found to antagonize the morpholog-
TABLE I
RhoGDI inhibition of GEF-exchange activity (units s1  sd.)
2 M phosphorylated or control GST-RhoA proteins were incubated
with the indicated amount of RhoGDI (GDI) prior to the addition of
Vav2. Linear velocity with standard deviation was calculated as de-
scribed under “Experimental Procedures.” For comparison, -fold induc-
tion of nucleotide uptake upon Vav-2 addition (Vav-2 exchange/basal
uptake) and the percent inhibition of this induction are provided.
RhoGDI inhibition of Vav2-induced nucleotide exchange was more ro-
bust for phosphorylated RhoA than control protein.
Condition RhoA RhoA-phosphorylated
Basal 0.98  0.15 0.87  0.13
150 nM Vav2 3.84  0.21 (3.9-fold) 3.52  0.27 (4.1-fold)
 0.5 M GDI 3.08  0.30 (81%) 3.26  0.33 (93%)
 1.0 M GDI 2.83  0.22 (74%) 2.37  0.34 (67%)a
 2.0 M GDI 2.34  0.28 (61%) 1.51  0.28 (43%)a
a p  0.01.
FIG. 4. RhoA phosphorylation promotes RhoGDI interaction.
A, GST-RhoA or GST-RhoA serine mutants, as indicated, were allowed
to equilibrate for 15 min prior to the addition of the DH/PH/CRD Vav2
and mant-GTP. Vav2 promoted an equivalent linear exchange velocity
for all GST-RhoA proteins. B, equal molar amounts of RhoGDI and
GST-RhoA proteins (2 M) were equilibrated with GST-RhoA proteins
for 15 min prior to addition of DH/PH/CRD of Vav2. RhoGDI inhibition
of GEF exchanges results in a slower and more sustained linear ex-
change velocity for all RhoA proteins compared with A. The linear
exchange velocities of the two phosphomimetics, GST-RhoA(S188D)
and GST-RhoA(S188E), were significantly depressed compared with
GST-RhoA and GST-RhoA(S188A) protein controls.
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ical affects of cAMP (23); therefore the effects of forskolin on
stress fiber organization were examined for the stable clones.
Mock-expressing cells revealed dissolution of stress fibers fol-
lowing forskolin activation of adenylate cyclase (Fig. 10, panel
above line). A minority of cells expressing wild-type Myc-RhoA
were protected from filamentous actin disassembly, whereas
cells expressing Myc-RhoA(S188A) were completely protected
against the morphological affects of cAMP (Fig. 10, panels
below line). On the other hand, both Myc-RhoA(S188E)-ex-
pressing clones uniformly displayed stress fiber dissolution
(Fig. 10, panels below line). Together, these data provide evi-
dence that addition of a negative charge to Ser188 by phospho-
rylation is sufficient to attenuate RhoA activity.
DISCUSSION
In agreement with previous work (13, 19, 23), we found that
RhoA is an excellent substrate for PKA. Additionally, we dis-
covered that RhoG, but not Cdc42 or Rac1, was also phospho-
rylated by PKA. Although RhoA, RhoG, and Cdc42 possess
carboxyl serine residues, the preceding three amino acids that
target PKA diverge. Although RhoA, Rap1a, and Rap1b, all
contain three lysines (KKKS), Cdc42 (PKKS) contains a proline
turn in place of the initial basic residue, a divergence that may
explain why Cdc42 is a poorer substrate than RhoA in vitro
(33). On the other hand, RhoG (KRGRS) contains a glycine
flanked by three basic residues, a motif more consistent with
KKKS. The significance of RhoG phosphorylation is unknown
and currently under investigation.
Unlike Rap1a and Rap1b, which are easily isolated as phos-
phoproteins from cells (15, 16), a clear demonstration of intra-
cellular RhoA phosphorylation is lacking. Lang et al. (13) were
able to immunoprecipitate only small amounts of 32P-labeled
RhoA from intact cells, whereas Essler et al. (38) reported
recently that a significant charge shift of RhoA was not ob-
served following cAMP stimulation of HUVEC cells. To address
this problem, we created antibodies that specifically recognize
the phosphorylated form of RhoA. When expressed in cells, the
non-prenylated RhoA (C190A) was a cellular target of PKA
following forskolin stimulation and during cell spreading, an
event associated with low RhoA (32, 34) and high PKA activity
(35, 36). Although limited by antibody constraints, these re-
sults provide the first conclusive evidence, at least in the case
of non-prenylated RhoA, that Ser188 is phosphorylated in re-
sponse to cellular PKA activation in vivo.
Treatment of cells with cAMP or cGMP agonists is associated
TABLE II
RhoGDI inhibition of GEF-exchange activity (units s1  S.D.)
2 M GST-RhoA or GST-RhoA serine mutant proteins were incubated with the indicated amount of RhoGDI (GDI) prior to the addition of Vav2.
Data are presented as described for Table I. RhoGDI inhibited Vav2-induced nucleotide exchange of phosphomimetic proteins to a greater extent
than control proteins. RhoGDI inhibition was more pronounced for GST-RhoA(S188E) than GST-RhoA(S188D).
Condition wtRhoA RhoA-S188A RhoA-S188D RhoA-S188E
Basal 1.09  0.11 0.98  0.12 0.89  .06 0.93  0.08
150 nM Vav2 6.84  0.33 (6.3-fold) 6.75  0.31 (6.9-fold) 6.67  0.40 (7.4-fold) 6.47  0.17 (6.9-fold)
 0.5 M GDI 5.74  0.30 (81%) 5.55  0.36 (79%) 5.89  0.22 (86%) 4.50  0.13 (64%)a
 1.0 M GDI 4.27  0.18 (55%) 4.16  0.13 (55%) 3.28  0.19 (41%)a 2.89  0.23 (35%)a
 2.0 M GDI 2.74  0.19 (29%) 2.53  0.14 (27%) 1.72  0.12 (14%)a 1.53  0.10 (11%)a
a p  0.01.
FIG. 5. RhoA phosphorylation does not affect p190RhoGAP activity. A, Rho GTPase activity was indirectly examined by incubating cPKA
phosphorylated (white symbol) or control GST-RhoA (black symbol) preloaded with GTP in the presence of a coumarin-tagged phosphate-binding
protein whose fluorescence increases (465 nm) following binding of phosphate released from GTP. Addition of 250 or 750 pM p190RhoGAP-
stimulated GAP activity was not affected by RhoA serine phosphorylation. B, GST-RhoA (black symbol), GST-RhoA(S188A) (gray symbol), and
GST-RhoA(S188E) (white symbol) were treated as in A. The presence of a phosphomimetic residue does not directly influence p190RhoGAP activity.
GTP-loaded RhoA (C) or GTP-loaded ggRhoA (prenylated) (D) were stimulated with p190RhoGAP (500 pM) as indicated. Basal and GAP-induced
activity of phosphorylated ggRhoA (gray curves) was consistent with control ggRhoA (black curves). Both basal and stimulated GTPase activities
of unmodified RhoA proteins were slightly higher than their prenylated counterparts (basal initial linear velocity (% hydrolysis min1  S.D.) of
RhoA, phosphorylated RhoA, ggRhoA, and phosphorylated ggRhoA was 1.95  0.15, 1.66  0.18, 1.66  0.17, and 1.50  0.26, and stimulated was
5.50  0.40, 5.13  0.32, 3.96  0.32, and 3.96  0.20).
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with translocation of RhoA from membranes (13, 14). Non-
prenylated RhoA is efficiently phosphorylated within the cell
(Fig. 2), suggesting that it may be a target of PKA regulation.
We therefore analyzed whether Ser188 phosphorylation con-
trols RhoA cycling by impeding prenylation. In vitro assays
demonstrated that geranylgeranyl transferase activity was not
sensitive to the presence of a phosphate on Ser188. As events of
Rho protein prenylation are poorly understood, it remains pos-
sible that phosphorylation of this residue affects post-transla-
tion modification of RhoA through mechanisms not reflected by
in vitro assays. However, regulating RhoA cycling at the step of
prenylation appears to be an inefficient and long term ap-
proach for a kinase that depends on localized and transient
activity (reviewed in Ref. 39).
We found that transiently expressed phosphomimetic Myc-
RhoA proteins were poorly loaded with GTP nucleotides com-
pared with control proteins. We also demonstrated that Myc-
RhoA(S188E) protein signaling is significantly attenuated
compared with control proteins and that this difference was not
reflected in the GTP-loading profiles of stably transfected cells.
Both of these results are consistent with enhanced sequestra-
tion of Myc-RhoA(S188E) by RhoGDI. In the case of transiently
expressed protein, sequestration by RhoGDI would reduce the
accessibility of GEFs, as is observed in vitro (Tables I and II). In
the case of stably expressed proteins, Myc-RhoA(S188E) that has
become GTP-loaded over time could still be aberrantly seques-
tered by RhoGDI. This would be reflected by low RhoA activity in
the cell (see Figs. 9 and 10) but not by RBD pulldowns because of
a limitation of the assay. The lysis conditions of RBD pulldown
assays requires disruption of both RhoA(GTP)membrane and
RhoA(GTP)effector complexes to form RhoA(GTP)GST-RBD
complexes that are driven by the vast molar excess of GST fusion
FIG. 6. RhoA phosphorylation does not affect geranylgeranyl
transferase activity. A, duplicate phosphorylated or control GST-
RhoA were incubated with 3H-geranylgeranyl pyrophosphate and gera-
nylgeranyl transferase for 20 or 60 min, and the extent of prenylation
was visualized by SDS-PAGE followed by autoradiography. B, GST-
RhoA-Sepharose was phosphorylated as described under “Experimental
Procedures” and then incubated with 3H-geranylgeranyl pyrophosphate
and geranylgeranyl transferase for the indicated times and then repeat-
edly washed, and the extent of prenylation was calculated by measuring
radiation counts released per min. Values represent two independent
reactions  S.D. C, duplicate samples of GST-RhoA, GST-RhoA(C190A)
(cannot be prenylated), and GST-RhoA Ser188 mutants were incubated
with 3H-geranylgeranyl pyrophosphate and geranylgeranyl transferase
for 20 min, and the extent of prenylation was visualized by SDS-PAGE
followed by autoradiography.
FIG. 7. GTP loading of transiently expressed Myc-RhoA pro-
teins. A, the indicated Myc-RhoA proteins were transiently transfected
in duplicate for each protein and then collected and processed for GTP
loading as described under “Experimental Procedures.” B, three indi-
vidual experiments done in duplicate were scanned and quantified by
densitometry as described under “Experimental Procedures.” The ratios
of GTP-loaded Myc-RhoA to total Myc-RhoA were normalized to wild-
type Myc-RhoA values. Error bars denote standard deviation of GTP
loading (*, p  0.01 compared with wild-type and Myc-RhoA(S188A)
proteins).
FIG. 8. Evaluation of NIH 3T3 cells stably expressing Myc-
RhoA protein. Two isolated clones were chosen for each Myc-RhoA
protein based on expression level. A, upper panel, lysates were collected
from the indicated clone and Western blotted with an anti-RhoA mono-
clonal antibody. Myc-RhoA migrated at a higher molecular weight in
20% SDS-PAGE gels and was expressed at considerably lower amounts
than endogenous RhoA. Lower panel, the above blot was stripped and
re-probed with an anti-Myc antibody. B, stable Myc-RhoA clones were
collected and processed for GTP-loading profiles. GST-RBD pulldowns
were blotted with the anti-Myc antibody to specifically show loading of
exogenous Myc-RhoA protein. Unlike during transient expression con-
ditions, GTP loading of Myc-RhoA(S188E) proteins were comparable
with Myc-RhoA(S188A) proteins. Myc-RhoA(C190A) had a depressed
level of GTP loading compared with other RhoA proteins.
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protein. Not unexpectedly, we found that the lysis conditions
completely disrupt RhoARhoGDI complexes,2 and have been
unable to find lysis conditions that liberate RhoA(GTP) for RBD
pulldown assays and preserve RhoARhoGDI binding. It is prob-
able, therefore, that a portion of the stably expressed and GTP-
loaded Myc-RhoA(S188E) protein is released from inactive
RhoA(GTP)RhoGDI pools, in addition to active RhoA-
(GTP)effector complexes. Thus, GST-RBD pulldowns, while an
effective tool for measuring RhoGAP-mediated inhibition (34) or
GEF activation of RhoA (31), will not reflect RhoGDI inhibition
by sequestration.
In addition to enhanced binding to RhoGDI, Myc-
RhoA(S188E) proteins may have lower binding affinity to an
effector, such as Rho kinase (23). However, we found that
constitutively active GST-RhoA(63L, S188E) was as efficient as
GST-RhoA(63L, S188A) proteins in pulling down Rho kinase
from NIH cell lysates.3 Further, stably expressed phosphomi-
metic RhoA proteins bound the RBD domain of the Rho effector
Rhotekin (Fig. 8B). Therefore, we propose that attenuation of
phosphomimetic RhoA activation and activity is because of
cytosolic sequestration of RhoA driven by enhanced RhoGDI
interactions that are observed in vitro.
The data presented here provide information regarding
RhoA phosphorylation in context of regulatory protein interac-
tions and demonstrate that the addition of a negative charge to
Ser188 is sufficient to diminish both RhoA activation and activ-
ity within the context of a cell. As PKA also uncouples GEF
activation from receptor stimulation (26, 37) and antagonizes
microfilament integrity by directly phosphorylating and inhib-
iting myosin light chain kinase (40), it is becoming clear that
PKA inhibits RhoA signaling pathways at multiple levels. It
will be important in future work to establish where and when
RhoA phosphorylation occurs within the cell and to address
whether PKA phosphorylation works in parallel with RhoGAP-
mediated inhibition of RhoA during events of cell protrusion
and migration.
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